- The scheme provides incentives (4% to 6%) on incremental sales.
- This encourages companies to increase their manufacturing output.
- For pharma, it incentivizes setting up indigenous Greenfield/Brownfield investment.
- This aims to boost domestic manufacturing and reduce import dependence.
- By making domestic manufacturing more competitive, it aims to enhance exports.
- The text implies a positive impact on output and exports.